Ubiquigent, a drug discovery firm specialising in ubiquitin cell-signalling, has received £500k ($800k) investment from commercialisation firm the IP Group and government agency Scottish Enterprise (SE), via SE’s investment arm the Scottish Investment Bank.

The firm, which is a spin-out of the University of Dundee and still located on campus, will use the latest round of funding to accelerate development and commercialisation of its drug discovery platforms.

Ubiquigent also announced that Dr Mark Tregerne, a pharmaceutical industry veteran with 25…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?